X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SPN-830 (apomorphine) is a novel and less invasive therapy, which acts as dopamine D2 receptor agonist, and is investigated for the treatment of motor fluctuations (OFF episodes) in Parkinson’s disease.
Lead Product(s): Apomorphine Hydrochloride
Therapeutic Area: Neurology Product Name: SPN-830
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2024
Details:
SPN-820 is a novel small molecule activator of the mechanistic target of rapamycin complex 1 (mTORC1) currently under phase 2 development for use in major depressive disorder.
Lead Product(s): SPN-820
Therapeutic Area: Psychiatry/Psychology Product Name: SPN-820
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Navitor Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2024
Details:
SPN-830 (apomorphine) is a novel and less invasive therapy, which is acts as dopamine D2 receptor agonist, which is investigated for the treatment of motor fluctuations (OFF episodes) in Parkinson’s disease.
Lead Product(s): Apomorphine Hydrochloride
Therapeutic Area: Neurology Product Name: SPN-830
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2023
Details:
SPN-830 (apomorphine) is a novel and less invasive therapy, which is acts as dopamine D2 receptor agonist, which is investigated for the treatment of motor fluctuations (OFF episodes) in Parkinson’s disease.
Lead Product(s): Apomorphine Hydrochloride
Therapeutic Area: Neurology Product Name: SPN-830
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2023
Details:
SPN-830 is an investigational apomorphine infusion device under review for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson’s disease (PD).
Lead Product(s): SPN-830
Therapeutic Area: Neurology Product Name: SPN-830
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2022
Details:
At daily flexible-dose 200 to 600mg, Phase III trial met primary endpoint showing reduction change from baseline of Adult ADHD Investigator Symptom Rating Scale total score at end of study was statistically significantly greater in adults treated with Qelbree versus placebo.
Lead Product(s): Viloxazine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Qelbree
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2022
Details:
U.S.FDA notice for company’s NDA, resubmission for SPN-830 for treatment of motor fluctuations in Parkinson’s disease is considered a standard review thereby assigning a timeline of 10 months for review by FDA and establishing a PDUFA target action date in early October 2022.
Lead Product(s): Apomorphine Hydrochloride
Therapeutic Area: Neurology Product Name: SPN-830
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2022
Details:
Company announced resubmission of NDA for SPN-830 (Apomorphine Hydrochloride) for the continuous treatment of motor fluctuations in Parkinson’s Disease.
Lead Product(s): Apomorphine Hydrochloride
Therapeutic Area: Neurology Product Name: SPN-830
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2021
Details:
Acquistion will strengthens Parkinson’s disease portfolio with GOCOVRI (amantadine) extended release capsules, the first and only FDA-approved medicine indicated for the treatment of both OFF and dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy.
Lead Product(s): Amantadine Hydrochloride
Therapeutic Area: Neurology Product Name: Gocovri
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Adamas Pharmaceuticals
Deal Size: $450.0 million Upfront Cash: $450.0 million
Deal Type: Acquisition November 24, 2021
Details:
The transaction will provide Supernus with two marketed products: GOCOVRI (amantadine) extended release capsules, indicated for both OFF and dyskinesia in patients with Parkinson’s disease and Osmolex ER (amantadine) tablets, approved for Parkinson’s disease.
Lead Product(s): Amantadine Hydrochloride
Therapeutic Area: Neurology Product Name: Gocovri
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Adamas Pharmaceuticals
Deal Size: $450.0 million Upfront Cash: $450.0 million
Deal Type: Acquisition October 11, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
